HA130 is a selective boronic acid-based inhibitor of autotaxin. Studies show that adminstration of HA130 in mice results in rapid decrease of the lipid mediator lysophosphatidic acid (LPA) in the circulation. These findings suggest that HA 150 may provide useful therapeutic strategy in treating disorders associated with vascular development, inflammation, fibrotic disease, and tumor progression.
HA 150 is a selective boronic acid-based inhibitor of autotaxin. Studies show that adminstration of HA 150 in mice results in rapid decrease of the lipid mediator lysophosphatidic acid (LPA) in the circulation. These findings suggest that HA 150 may provide useful therapeutic strategy in treating disorders associated with vascular development, inflammation, fibrotic disease, and tumor progression.
